La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Roadzen a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Roadzen..

Roadzen (NASDAQ:RDZN) Azioni, Catena delle Opzioni

Roadzen

Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.

Roadzen Inc

Piper Sandler analyst Rob Owens maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Neutral and raises the price target from $70 to $80.

News

Price Target

Analyst Ratings

FTNT

Piper Sandler Maintains Neutral on Fortinet, Raises Price Target to $80

Scotiabank analyst Patrick Colville maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Sector Outperform and raises the price target from $55 to $62.

Scotiabank Maintains Sector Outperform on Dynatrace, Raises Price Target to $62

WIIM

PEGY

Pineapple Energy shares are trading higher after the company announced distribution to contingent value rights holders.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>)</h3>
<ul>
<li>Dividend Yield: 11.24%</li>
<li>JP Morgan analyst Samik Chatterjee maintained an Underweight rating and cut the price target from $11 to $8 on Oct. 30. This analyst has an accuracy rate of 70%.</li>
<li>Loop Capital analyst Ananda Baruah maintained a Hold rating and slashed the price target from $14 to $11 on Aug. 14. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On Oct. 29, Xerox reported worse-than-expected third-quarter financial results and cut annual outlook.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">latest XRX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="890" height="813" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044607/image-88.png" alt="" class="wp-image-637170" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044607/image-88.png 890w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044607/image-88-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044607/image-88-768x702.png 768w" sizes="(max-width: 890px) 100vw, 890px" /></a></figure>
<h3 class="wp-block-heading">Silicon Motion Technology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>)</h3>
<ul>
<li>Dividend Yield: 3.57%</li>
<li>Needham analyst Quinn Bolton maintained a Buy rating and cut the price target from $94 to $75 on Nov. 1. This analyst has an accuracy rate of 79%.</li>
<li>Wedbush analyst Matt Bryson reiterated an Outperform rating with a price target of $90 on Oct. 2. This analyst has an accuracy rate of 81%.</li>
<li>Recent News: On Oct. 30, Silicon Motion Technology posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">latest SIMO news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="911" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044643/image-89.png" alt="" class="wp-image-637172" style="width:631px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044643/image-89.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044643/image-89-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044643/image-89-768x692.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>BMO Capital analyst Keith Bachman maintained a Market Perform rating and raised the price target from $235 to $260 on Oct. 24. This analyst has an accuracy rate of 81%.</li>
<li>Jefferies analyst Brent Thill maintained a Hold rating and increased the price target from $200 to $245 on Oct. 21. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: On Oct. 23, IBM reported third-quarter revenue of $14.968 billion, missing the consensus estimate of $15.07 billion, according to Benzinga Pro. The company reported quarterly loss from continuing operations of 34 cents per share.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">trend in IBM stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044754/image-90.png" alt="" class="wp-image-637173" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044754/image-90.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044754/image-90-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044754/image-90-768x693.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Dividends

Pre-Market Outlook

Markets

Trading Ideas

SIMO

Wall Street's Most Accurate Analysts Spotlight On 3 Tech Stocks With Over 3% Dividend Yields

Piper Sandler analyst Matt O'Brien maintains TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) with a Overweight and lowers the price target from $8 to $5.

TELA

Piper Sandler Maintains Overweight on TELA Bio, Lowers Price Target to $5

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.
Shares of Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/SG/earnings">quarterly financial results</a>.
Sweetgreen reported a quarterly loss of 18 cents per share, compared to market expectations for a loss of 16 cents per share. The company reported quarterly sales of $173.400 million which missed the analyst consensus estimate of $175.533 million.
Sweetgreen shares dipped 15% to $35.87 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) shares fell 33.6% to $16.31 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares fell 29% to $1.98 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) declined 26.6% to $5.75 in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) fell 14.1% to $9.85 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) shares dipped 12.7% to $29.62 in pre-market trading after the company reported worse-than-expected third-quarter EPS results.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) dipped 12.6% to $2.14 in pre-market trading after the company reported worse-than-expected third-quarter revenue results.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) declined 9.7% to $119.62 in pre-market trading following third-quarter results.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) fell 5.2% to $36.97 in pre-market trading after the company reported worse-than-expected third-quarter revenue results and lowered its FY24 revenue guidance..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Movers

DKNG

MRVI

PACB

PINS

RDFN

Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) released topline data from the Phase 3 WAYPOINT trial of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps])
The data <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/tezspire-nasal-polyps-trial-met-primary-endpoints.html" rel="noreferrer noopener">showed</a> that Tezspire&nbsp;demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38299995/amgenastrazenecas-asthma-drug-tezspire-vs-sanofiregenerons-blockbuster-dupixent-ana" rel="noreferrer noopener">Amgen/AstraZeneca&#8217;s Asthma Drug Tezspire Vs. Sanofi/Regeneron&#8217;s Blockbuster Dupixent &#8211; Analyst Gives His Pick</a>
WAYPOINT is a randomized, double-blind trial that evaluated the efficacy and safety of&nbsp;Tezspire&nbsp;administered subcutaneously compared to placebo in adults with severe CRSwNP.
Participants in the trial were symptomatic despite treatment with standard of care (intranasal corticosteroids [INCS]).
Chronic rhinosinusitis with nasal polyps is&nbsp;a condition that can cause symptoms from sinus pain and nose stuffiness to loss of smell. Nasal polyps are growths in the nose or sinuses.
The safety profile and tolerability of&nbsp;Tezspire in this trial were consistent with the known profile of the medicine.
Full results will be shared with regulatory authorities and the scientific community at an upcoming medical meeting.
Tezspire&nbsp;is currently approved for severe asthma in the US, EU, Japan, and nearly 60 countries.
It is approved as a single-use pre-filled syringe and auto-injector for self-administration in the US and EU.
In May, the companies announced the results of the Phase 2a COURSE trial of Tezspire for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic&nbsp;bronchitis, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38924821/amgenastrazeneca-say-asthma-drug-shows-activity-in-another-lung-disease-across-broad-patient-popu" rel="noreferrer noopener">or smoking status</a>.&nbsp;
The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significant.
Price Action: AMGN stock closed at $321.91 on Thursday, and AZN stock is up 0.11% at $64.76 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820820/solaredge-q3-results-miss-expectations-analysts-warn-of-cash-flow-challenges-and-ne" target="_blank" rel="noreferrer noopener">SolarEdge Q3 Results Miss Expectations; Analysts Warn Of Cash Flow Challenges And Need For Cost Cuts</a></li>
</ul>

Biotech

Large Cap

Health Care

General

AMGN

AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis

Piper Sandler analyst Matt Farrell reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Overweight and raises the price target from $110 to $140.

Reiteration

Piper Sandler Reiterates Overweight on Trade Desk, Raises Price Target to $140

Pineapple Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) ("Pineapple" or the "Company"), a leading provider of sustainable solar energy and backup power to households, businesses, municipalities, and for servicing existing systems, today announced that it will distribute to the holders of its non-transferable Contingent Value Rights ("CVRs") a payment of $850,269, or $0.35 per CVR.

Pineapple Energy Announces That It Will Distribute To The Holders Of Its Non-Transferable Contingent Value Rights A Payment Of $850,269, Or $0.35 Per CVR

INDI

Indie Semiconductor shares are trading higher after the company reported better-than-expected Q3 financial results.

Scotiabank analyst Patrick Colville maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Sector Outperform and lowers the price target from $135 to $133.

DDOG

Scotiabank Maintains Sector Outperform on Datadog, Lowers Price Target to $133

Servotronics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVT#AMEX">SVT</a>) reported quarterly losses of $(0.20) per share. This is a 122.22 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $12.43 million in sales this quarter. This is a 7.32 percent increase over sales of $11.58 million the same period last year.

Earnings

Servotronics Q3 EPS $(0.20) Down From $(0.09) YoY, Sales $12.43M Up From $11.58M YoY

RVNC

Revance Therapeutics shares are trading lower after the company reported better-than-expected Q3 EPS results.

Piper Sandler analyst Alexander Potter maintains ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) with a Neutral and raises the price target from $16 to $18.

ACVA

Piper Sandler Maintains Neutral on ACV Auctions, Raises Price Target to $18

The holiday season brings joy, family gatherings and sometimes, stress.
For those considering cannabis as a natural way to ease holiday nerves and connect with loved ones, one of Vermont's largests cannabis brands, Upstate Elevator Supply Co. has introduced the Happy Days and Dreamy Nights THC gummy bundle. With a mix of daytime and nighttime formulas, this set of microdosed gummies offers an option for a balanced, relaxing holiday experience.
See Also: <a href="https://www.benzinga.com/markets/cannabis/22/01/24922189/report-americans-are-celebrating-traditional-holidays-with-cannabis-spend-millions-doing-so">Report: Americans Are Celebrating Traditional Holidays With Cannabis, Spend Millions Doing So</a>
In this guide, we'll walk you through practical tips from Kelsy Raap, a certified community herbalist and Upstate's director of outreach and education, on how to incorporate cannabis into your holiday gatherings.
<h3 class="wp-block-heading">Microdosing 101: How To Start Small</h3>
For those trying cannabis edibles for the first time, particularly in a family setting, Raap recommends beginning with a microdose. "Start low," she advises. "One milligram is a good place to start for somebody that's never used cannabis or who doesn't use it regularly." 
Upstate's gummy pucks are pre-scored into precise 2mg wedges, allowing users to choose a small amount and adjust as needed. For newcomers, Raap suggests staying below 5mg, especially during social gatherings where moderation can make for a smoother experience.
To enhance the benefits while keeping the experience mellow, consider formulas that balance THC with other cannabinoids like CBD, CBG or CBN. "These compounds help balance the THC so that it doesn't feel quite as altering," Raap explains. For first-timers, this balance can provide all the therapeutic effects of THC without an overwhelming high.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1022" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-1022x1024.jpg" alt="" class="wp-image-636585" style="width:360px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-1022x1024.jpg 1022w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-300x300.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-150x150.jpg 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-768x769.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies.jpg 1078w" sizes="(max-width: 1022px) 100vw, 1022px" /><figcaption class="wp-element-caption">Image courtesy: Upstate Elevator.</figcaption></figure>
<h3 class="wp-block-heading">Easing Holiday Stress: How THC And CBD Work Together</h3>
Holiday stress is common, and for many, cannabis offers a natural way to manage it. Raap explains how the combined effects of CBD and THC can support relaxation, each working differently to calm the body and mind. 
"CBD, the non-intoxicating component, is great for helping us calm down, for helping sort of ease the mind in a very subtle, gentle way," she says. THC, on the other hand, can provide a more immediate sense of relaxation at low doses, making it a good choice for those who want to unwind without feeling overly sedated. Even a small amount, about one milligram, can soothe the nervous system and bring a sense of calm.
Microdosing THC, especially in social situations, can also help people take a step back from potentially tense conversations, adding a layer of objectivity. Raap notes that, at low doses, THC "helps us kind of zoom out, pull back, see things from a little bit more of a holistic perspective, and feel a little bit less personally involved in a conflict." For holiday gatherings where emotions might be heightened, especially after the U.S. elections, this approach can foster a more relaxed and open atmosphere.
<h3 class="wp-block-heading">Bringing Cannabis To The Family Table: How To Build Comfort And Trust</h3>
Cannabis at family occasions is gradually becoming more normalized, and Raap has seen this shift firsthand. 
 "One of my favorite things is when a customer walks into our store, who's, you know, 35, 40 years old, and they're bringing their parents in with them," she shares. This shift is often met with curiosity and surprise as parents rediscover cannabis, especially in a low-dose, controlled form.
Raap points out that today's cannabis products come with clear labeling and rigorous testing, which can ease the concerns of older generations. "There's a lot more trust in the companies now, right? Because everything is tested," she notes. 
For older adults, the transparency of listed ingredients and lab-tested dosages can offer peace of mind. These products are created to help bridge generations, allowing young adults to share the benefits of cannabis with their parents or grandparents in a safe, enjoyable way.
<h3 class="wp-block-heading">How to Talk Your Family Into Microdosing THC This Holiday Season</h3>
Introducing cannabis at family gatherings can be met with hesitation, but Raap offers a straightforward approach. "If a family is happy with the dynamics—if they&#8217;re mostly peaceful and calm, if they don&#8217;t have any challenges with fighting over politics or religion—then you don't need it." 
However, for families who find themselves in tense discussions or who want to keep things light, microdosing can be beneficial. "If a family is looking for a tool to help them have less reactivity during the holidays and be less reactive&#8230;this is a great tool."
For those worried about acting unpredictably, Raap reassures, "This isn't like alcohol, right? You're not going to make a fool of yourself if you use cannabis; you're not going to make poor decisions."
See Also: <a href="https://www.benzinga.com/markets/cannabis/19/04/13533938/a-really-nice-entry-point-cannabis-microdosing-and-who-its-for">&#8216;A Really Nice Entry Point&#8217;: Cannabis Microdosing And Who It&#8217;s For</a>
When legal concerns come up, Raap suggests focusing on the benefits. "Consider whether you're looking for the therapeutic application. There are different ways to use cannabis. You can use it therapeutically, you can use it recreationally."
<h3 class="wp-block-heading">Quick Tips For First-Time Edible Users</h3>
Here are Raap's top tips for a positive experience:
<ol>
<li>Start Low and Go Slow: For beginners, 1-2mg is a good starting point,and 5mg should be the upper limit for those less experienced with THC.</li>
<li>Balance with CBD: Look for formulas that blend THC with other cannabinoids like CBD to create a balanced effect.</li>
<li>Be Prepared for Too Much: If you or someone feels "too high," Raap suggests taking a large dose of CBD, which can help mitigate THC's psychoactive effects and bring you back to a more comfortable level. "Using a large dose of CBD will mitigate the psychoactivity," she says.</li>
</ol>
<h3 class="wp-block-heading">Beyond The Holidays: A Healthier Alternative To Alcohol</h3>
If you're considering cutting back on alcohol this New Year, cannabis may be a fun, non-alcoholic alternative. "I could still have three or four of these while my friends are drinking their six-pack of beer," Raap suggests, while pointing at one of Upstate&#8217;s THC beverages. 
THC allows for a festive mood without the dehydrating, hangover-inducing effects of alcohol, making it an appealing option for those looking to moderate their drinking habits.
THC can also help support mental wellness during the winter months. For those prone to seasonal depression or daily anxiety, Raap recommends a more consistent approach, integrating cannabis into a daily wellness routine. 
"For folks that experience anxiety and stress every single day…planning to implement a daily practice with CBD and or low-dose THC is a good idea," she explains. Microdosing daily or as needed can help build resilience against winter blues.
<h3 class="wp-block-heading">Will Cannabis Become The New Alcohol At Family Gatherings?</h3>
Looking toward the future, Raap says she hopes cannabis will eventually be as accepted as alcohol at family events. "Honestly, I think that alcohol eventually is going to go the way of cigarettes," she says.
However, she notes that federal legalization would likely be necessary for widespread acceptance. "A lot of people still trust the government, and if the government says it's bad for you, they believe it," Raap added.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39585412/hand-in-hand-progressive-reform-galvanizes-interest-in-microdosing-new-study-shows">Reform Is Pushing Curiosity In Microdosing, Study Shows</a></li>
</ul>
Cover image made with AI.

Cannabis

Exclusives

Interview

How To Microdose Cannabis For Stress-Free Holiday Season: Tips For Newcomers

Agilon Health shares are trading lower after William Blair downgraded the stock from Outperform to Market Perform.

Scotiabank analyst Mario Saric maintains CROMBIE REAL STATE INVESTMENT TRUST (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CRR#TSX">CRR</a>) with a Sector Outperform and raises the price target from C$16 to C$16.5.

TSX:CRR

Scotiabank Maintains Sector Outperform on CROMBIE REAL STATE INVESTMENT TRUST, Raises Price Target to C$16.5

Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Neutral and raises the price target from $71 to $75.

SOLV

Piper Sandler Maintains Neutral on Solventum, Raises Price Target to $75

Maravai LifeSciences shares are trading lower after William Blair downgraded the stock from Outperform to Market Perform and Baird cut its price target from $10 to $9.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announced a price target of $33. Cidara Therapeutics shares closed at $13.11 on Thursday. <a href="https://www.benzinga.com/quote/cdtx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Leonid Timashev initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with an Outperform rating and announced a price target of $80. Cytokinetics shares closed at $55.84 on Thursday. <a href="https://www.benzinga.com/quote/cytk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Sudan Loganathan initiated coverage on Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) with an Overweight rating and announced a price target of $30. Immunome shares closed at $12.54 on Thursday. <a href="https://www.benzinga.com/quote/imnm/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Dennis Ding initiated coverage on Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) with a Buy rating and announced a price target of $8. Inhibikase Therapeutics shares closed at $2.78 on Thursday. <a href="https://www.benzinga.com/quote/ikt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Ben Shelley initiated coverage on Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announced a price target of $306. Flutter Entertainment shares closed at $237.98 on Thursday. <a href="https://www.benzinga.com/quote/flut/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png" alt="" class="wp-image-637640" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084118/image-92.png 1237w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Initiation

CDTX

CYTK

FLUT

IMNM

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Roadzen Inc., Ocean Power Technologies, and Versus Systems are the 3 Penny Stocks to watch on July 4, based on&nbsp;TipRanks' Penny Stock Screener ...

3 Penny Stocks to Watch Now, 7/4/24

Roadzen Inc (RDZN) has provided an update. Xavier Blanchard, the Global Head of Strategy and Insurance at Roadzen Inc., has mutually agreed to term...

Roadzen Inc. Announces Strategic Transition of Leadership

An update from Roadzen Inc (RDZN) is now available. Roadzen Inc. has devised a strategic maneuver to mitigate its short-term debt burden by $3.5 mi...

Roadzen Inc. Converts Debt into Equity with Insider Participation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Tuesday as we check out all of the hottest news moving shares this morning.



Moving stocks are several new deals, delisting notices and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Vicinity Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/vev-stock-quote/">VEV</a>) stock is rocketing more than 153% alongside heavy pre-market trading.</li>



<li>CXApp (NASDAQ:<a href="https://investorplace.com/stock-quotes/cxai-stock-quote/">CXAI</a>) shares are soaring over 61% after <a href="https://www.nasdaq.com/press-release/cxapp-inc-nasdaq-cxai-announces-largest-expansion-deal-strategic-multi-year-0">signing an expansion deal</a> with Google Cloud.</li>



<li>MKDWell Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/mkdw-stock-quote/">MKDW</a>) stock is surging more than 57% alongside <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318514393&amp;type=PDF&amp;symbol=MKDW&amp;cdn=59d6d4925634abb97d78eb6b63a094fb&amp;companyName=MKDWELL+Tech+Inc.&amp;formType=SC+13D&amp;formDescription=General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-08-12">new investment news</a>.</li>



<li>Pono Capital Two (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptwo-stock-quote/">PTWO</a>) shares are rising over 37% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318512443&amp;type=PDF&amp;symbol=PTWO&amp;cdn=c007f907da889b37797c3a70ef100ef9&amp;companyName=Pono+Capital+Two+Inc.&amp;formType=DEFM14A&amp;formDescription=Definitive+proxy+statement+relating+to+merger+or+acquisition&amp;dateFiled=2024-08-12">proposed merger plan</a>.</li>



<li>Psychemedics (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmd-stock-quote/">PMD</a>) stock is increasing more than 20% on <a href="https://www.nasdaq.com/press-release/psychemedics-corporations-board-directors-approves-plan-terminate-registration-its">plans to delist its shares</a>.</li>



<li>Hesai (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsai-stock-quote/">HSAI</a>) shares are climbing over 19% without any clear news.</li>



<li>Roadzen (NASDAQ:<a href="https://investorplace.com/stock-quotes/rdzn-stock-quote/">RDZN</a>) stock is heading more than 18% higher despite a lack of news today.</li>



<li>QT Imaging (NASDAQ:<a href="https://investorplace.com/stock-quotes/qti-stock-quote/">QTI</a>) shares are getting an over 17% boost on Tuesday morning.</li>



<li>Adagio Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/">ADGM</a>) stock is jumping more than 17% without any recent news.</li>



<li>GCT Semiconductor (NYSE:<a href="https://investorplace.com/stock-quotes/gcts-stock-quote/">GCTS</a>) shares are up over 17% after <a href="https://www.nasdaq.com/press-release/gct-semiconductor-signs-mou-samsung-accelerate-development-4g-5g-chipsets-and-modules">signing an agreement</a> with Samsung.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Syros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/syrs-stock-quote/">SYRS</a>) stock is crashing more than 58% on a <a href="https://www.nasdaq.com/press-release/syros-provides-update-select-aml-1-phase-2-clinical-trial-2024-08-12">Phase 2 clinical trial update</a>.</li>



<li>PS International (NASDAQ:<a href="https://investorplace.com/stock-quotes/psig-stock-quote/">PSIG</a>) shares are diving over 21% <a href="https://investorplace.com/2024/08/why-is-ps-international-psig-stock-up-64-today/">after a massive rally yesterday</a>.</li>



<li>SunPower (NASDAQ:<a href="https://investorplace.com/stock-quotes/spwr-stock-quote/">SPWR</a>) stock is tumbling more than 19% on a <a href="https://finance.yahoo.com/news/sunpower-announces-nasdaq-delisting-notification-205800088.html">Nasdaq delisting notification</a>.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are taking an over 18% beating after rallying yesterday <a href="https://investorplace.com/2024/08/why-is-greenlane-gnln-stock-up-210-today/">on Safety Strips news</a>.</li>



<li>Surf Air Mobility (NYSE:<a href="https://investorplace.com/stock-quotes/srfm-stock-quote/">SRFM</a>) stock is sliding more than 18% after announcing an <a href="https://www.tipranks.com/news/company-announcements/surf-air-mobility-announces-optimistic-ai-joint-venture">artificial intelligence (AI) joint venture</a>.</li>



<li>HNR Acquisition (NYSEMKT:<a href="https://investorplace.com/stock-quotes/hnra-stock-quote/">HNRA</a>) shares are decreasing close to 16% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318511957&amp;type=PDF&amp;symbol=HNRA&amp;cdn=eb4e7e579bfe6b9a9328f0eca81fc1b2&amp;companyName=HNR+Acquisition+Corp+Class+A&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-08-12">proposed secondary offering</a>.</li>



<li>FSD Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/huge-stock-quote/">HUGE</a>) stock is retreating over 15% <a href="https://investorplace.com/2024/08/fsd-pharma-is-up-216-today-what-is-going-on-with-huge-stock/">after a Monday rally</a>.</li>



<li>Interactive Strength (NASDAQ:<a href="https://investorplace.com/stock-quotes/trnr-stock-quote/">TRNR</a>) shares are dropping more than 15% <a href="https://investorplace.com/2024/08/why-is-interactive-strength-trnr-stock-up-59-today/">following a rally yesterday</a>.</li>



<li>Yatra Online (NASDAQ:<a href="https://investorplace.com/stock-quotes/ytra-stock-quote/">YTRA</a>) stock is falling over 14% on a <a href="https://www.tipranks.com/news/company-announcements/yatra-online-reports-mixed-quarterly-performance">mixed earnings report</a>.</li>



<li>Conifer (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnfr-stock-quote/">CNFR</a>) shares are down more than 12% ahead of an <a href="https://www.nasdaq.com/press-release/conifer-holdings-schedules-second-quarter-2024-earnings-conference-call-webcast">earnings conference call tomorrow</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-aug-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Roadzen (NASDAQ:<a href="https://investorplace.com/stock-quotes/rdzn-stock-quote/">RDZN</a>) just reported results for the first quarter of 2025.<ul><li>Roadzen reported earnings per share of -46 cents. This was below the analyst estimate for EPS of -35 cents.</li><li>The company reported revenue of $8.93 million.</li><li>This was 1.09% worse than the analyst estimate for revenue of $9.03 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rdzn-stock-earnings-roadzen-for-q1-of-2025/">RDZN Stock Earnings: Roadzen Misses EPS, Misses Revenue for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RDZN Stock Earnings: Roadzen Misses EPS, Misses Revenue for Q1 2025

Roadzen GAAP EPS of -$0.71 misses by $0.38, revenue of $8.9M misses by $3.74M

Roadzen Inc ( ($RDZN) ) has shared an update. Roadzen Inc. is set to revolutionize the global auto insurance industry with its AI-driven platform, ...

Roadzen Inc. Unveils AI-Driven Auto Insurance Innovations

Roadzen says its insiders and major shareholders extend lock-up agreements for another year

ThinkEquity initiated coverage of Roadzen (RDZN) with a Buy rating and $6 price target Roadzen is an "Insurtech company transforming global auto in...

Roadzen initiated with a Buy at ThinkEquity

17:27 EDT Roadzen (RDZN) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking f...

Roadzen files $100M mixed securities shelf

ADGM

CNFR

CXAI

GCTS

GNLN

HNRA

HSAI

HUGE

MKDW

OPTT

PSIG

PTWO

RDZN

SPWR

SRFM

SYRS

TRNR

YTRA

Contracts

Press Releases

Roadzen's xClaim Platform Selected by Top 6 Indian P&C Insurer to Bring AI to Claims Processing

Roadzen Reports Record Revenue Growth in its First Fiscal Year as a Public Company

Roadzen CEO and Chairman Agree to Exchange $3.5 Million of Short-Term Debt for Equity in the Company

Financing

Roadzen Secures Mizuho Debt Extension and Facility Increase

Roadzen Named One of CNBC's World's Top InsurTech Companies for 2024

Roadzen Reports its Best Fiscal First Quarter Results in Q1 2025 Buoyed By Strong Year-Over-Year Revenue Growth and Addition of Several Marquee Clients

Roadzen to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

Roadzen's Insiders and Major Shareholders Agree to Extend Lock-Up for an Additional Year

Roadzen to Present at the ThinkEquity Investor Conference October 30, 2024

Roadzen Unveils MixtapeAI: Next-Generation AI Agents for the Insurance Industry

ReAlpha Tech

XIAO-I Corporation - American Depositary Shares

XIAO-I

Argo Blockchain plc - American Depositary Shares

Argo Blockchain

Arqit Quantum

Aware

Gorilla Technology Group Inc. - Ordinary shares

Gorilla Tech Gr

MicroCloud Hologram Inc. - Ordinary Shares

MicroCloud Hologram

Intellicheck

Issuer Direct

LivePerson

WM Technology, Inc. - Class A Common Stock

WM Tech

Mercurity Fintech Holding Inc. - American Ordinary Shares

Mercurity Fintech Holding

Mawson Infrastructure Group Inc. - Common Stock

Mawson Infra Gr

MMTEC

The9 Limited - American Depository Shares

The9

NiSun Intl Enterprise Development Group Co, Ltd - Class A Common Shares

NiSun Intl Enterprise Dev

OneConnect Financial Technology Co., Ltd. American Depositary Shares, each representing thirty ordinary shares

Comments

Roadzen

Roadzen (RDZN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO